SML2673
Deferasirox
≥98% (HPLC), iron chelator, powder
Synonym(s):
4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H15N3O4
CAS Number:
Molecular Weight:
373.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
Deferasirox, ≥98% (HPLC)
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O
InChI
1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+
InChI key
FMSOAWSKCWYLBB-VBGLAJCLSA-N
Application
Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.
Biochem/physiol Actions
Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator
Still not finding the right product?
Explore all of our products under Deferasirox
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Claudia Bollig et al.
The Cochrane database of systematic reviews, 8, CD007476-CD007476 (2017-08-16)
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective;
Abbas Rahdar et al.
Life sciences, 270, 119146-119146 (2021-02-06)
Deferasirox (DFX) was formulated into oil-in-water microemulsions in the presence of pluronicto improve its oral bioavailability. The size of the DFX-loadedmicroemulsions system measured by dynamic light scattering (DLS) was about 9 nm. The anti-proliferative and anti-lipid peroxidation effects of DFX and
Nesma Ahmed Safwat et al.
Pediatric research, 89(1), 185-190 (2020-06-17)
The genetic variants of the receptor for advanced glycation end products (RAGE) gene have been associated with vascular disease risk. The objective of this work was to explore the association of three single-nucleotide polymorphisms (SNPs) of RAGE gene (374T/A, 429T/C